Exploring the Impact of Hepatic Impairment on Pralsetinib Pharmacokinetics
Pralsetinib is a kinase inhibitor indicated for the treatment of metastatic rearranged during transfection (<i>RET</i>) fusion-positive non-small cell lung cancer. Pralsetinib is primarily eliminated by the liver and hence hepatic impairment (HI) is likely alter its pharmacokinetics (PK)...
Bewaard in:
| Hoofdauteurs: | , , , , , , , |
|---|---|
| Formaat: | Boek |
| Gepubliceerd in: |
MDPI AG,
2024-04-01T00:00:00Z.
|
| Onderwerpen: | |
| Online toegang: | Connect to this object online. |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|
Internet
Connect to this object online.3rd Floor Main Library
| Plaatsingsnummer: |
A1234.567 |
|---|---|
| Kopie 1 | Beschikbaar |